AnaptysBio, Inc. ANAB Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $258M— | —— | $0-100% | $93M+55.0% | |
| License | $9.6M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AnaptysBio, Inc. break its business down?
- AnaptysBio, Inc. (ANAB) reports revenue by business across 2 parts — Biopharma Company and Royalty Management Company. Each is extracted from the segment footnotes and tracked over time.
- Where does AnaptysBio, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AnaptysBio, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.